Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids
- PMID: 17299076
- DOI: 10.1210/jc.2006-1800
Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids
Abstract
Context: Graves' orbitopathy (GO) is probably caused by autoimmune reactions against autoantigen(s) shared by thyroid and orbital tissues sustained by intrathyroidal autoreactive T-lymphocytes infiltrating the orbit. Total thyroid ablation (TTA) may be beneficial for GO through removal of shared antigen(s) and autoreactive T-lymphocytes, but randomized studies are lacking.
Objective: Our objective was to evaluate the effects of TTA in patients with GO treated with iv glucocorticoids (GC).
Design/setting: A prospective, single-blind, randomized study was conducted at a referral center.
Patients/interventions: Sixty patients with mild to moderate GO were randomized into: 1) near-total thyroidectomy (TX); or 2) TX plus (131)I (TTA) groups, and then treated with iv GC. Patients were evaluated 3 and 9 months after iv GC.
Main outcome measure: Overall improvement of GO at 9 months was the main outcome measure.
Results: The distribution of GO outcome at 9 months was significantly more favorable in TTA than in TX patients (P = 0.0014 by chi(2) test). A cumulative significant (P = 0.0054) difference between the two groups at 3 and 9 months was found using a generalized linear model. Radioiodine uptake test and thyroglobulin assay in a patient sample showed complete ablation in the majority of TTA, but not of TX patients.
Conclusions: Compared with thyroidectomy alone, TTA is followed by a better outcome of GO in patients given iv GC. Whether TTA maintains this advantage in the long-term remains to be established.
Similar articles
-
Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.J Clin Endocrinol Metab. 2014 May;99(5):1783-9. doi: 10.1210/jc.2013-3093. Epub 2014 Jan 16. J Clin Endocrinol Metab. 2014. PMID: 24432992 Clinical Trial.
-
Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial.J Clin Endocrinol Metab. 2012 Jan;97(1):E44-8. doi: 10.1210/jc.2011-2077. Epub 2011 Oct 26. J Clin Endocrinol Metab. 2012. PMID: 22031515 Clinical Trial.
-
Total thyroid ablation in Graves' orbitopathy.J Endocrinol Invest. 2015 Aug;38(8):809-15. doi: 10.1007/s40618-015-0255-1. Epub 2015 Mar 5. J Endocrinol Invest. 2015. PMID: 25740065 Review.
-
Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.J Endocrinol Invest. 2021 Dec;44(12):2575-2579. doi: 10.1007/s40618-021-01544-1. Epub 2021 Apr 12. J Endocrinol Invest. 2021. PMID: 33844165 Free PMC article.
-
Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):325-37. doi: 10.1016/j.beem.2011.11.005. Best Pract Res Clin Endocrinol Metab. 2012. PMID: 22632369 Review.
Cited by
-
Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients.J Korean Med Sci. 2020 Jun 15;35(23):e177. doi: 10.3346/jkms.2020.35.e177. J Korean Med Sci. 2020. PMID: 32537950 Free PMC article.
-
Graves' orbitopathy: Management of difficult cases.Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S150-2. doi: 10.4103/2230-8210.104026. Indian J Endocrinol Metab. 2012. PMID: 23565365 Free PMC article.
-
The evaluation and treatment of graves ophthalmopathy.Med Clin North Am. 2012 Mar;96(2):311-28. doi: 10.1016/j.mcna.2012.01.014. Epub 2012 Feb 22. Med Clin North Am. 2012. PMID: 22443978 Free PMC article. Review.
-
Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.J Endocrinol Invest. 2016 Nov;39(11):1225-1233. doi: 10.1007/s40618-016-0484-y. Epub 2016 May 24. J Endocrinol Invest. 2016. PMID: 27220843
-
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?J Endocrinol Invest. 2025 Sep;48(9):1927-1950. doi: 10.1007/s40618-025-02653-x. Epub 2025 Aug 6. J Endocrinol Invest. 2025. PMID: 40768183 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous